Parkinsonism: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(4 intermediate revisions by 4 users not shown)
Line 31: Line 31:
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
| '''Drug Side Effect'''
| '''Drug Side Effect'''
|bgcolor="Beige"| [[Cytarabine]], [[Thioridazine hydrochloride]]
|bgcolor="Beige"| [[Cytarabine]], [[Fluphenazine]], [[Perphenazine]], [[Thiothixene]], [[Thioridazine hydrochloride]]
|-
|-
|-bgcolor="LightSteelBlue"
|-bgcolor="LightSteelBlue"
Line 131: Line 131:
{{col-break|width=33%}}
{{col-break|width=33%}}
* [[Cytarabine]]
* [[Cytarabine]]
* [[Thioridazine hydrochloride]]


{{col-break|width=33%}}
{{col-break|width=33%}}
Line 161: Line 162:
{{WS}}
{{WS}}


[[Category:Primary care]]
[[Category:Neurology]]
[[Category:Neurology]]
[[Category:Geriatrics]]
[[Category:Geriatrics]]
[[Category:Disease]]
[[Category:Disease]]

Latest revision as of 23:35, 29 July 2020

For patient information click here

Parkinsonism Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Parkinsonism from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Parkinsonism On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Parkinsonism

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Parkinsonism

CDC onParkinsonism

Parkinsonism in the news

Blogs on Parkinsonism

Directions to Hospitals Treating Parkinsonism

Risk calculators and risk factors for Parkinsonism

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Synonyms and keywords: Parkinson's syndrome; atypical Parkinson's; secondary Parkinson's

Overview

Historical Perspective

Pathophysiology

Causes

Causes by Organ System

Cardiovascular No underlying causes
Chemical/Poisoning No underlying causes
Dental No underlying causes
Dermatologic No underlying causes
Drug Side Effect Cytarabine, Fluphenazine, Perphenazine, Thiothixene, Thioridazine hydrochloride
Ear Nose Throat No underlying causes
Endocrine No underlying causes
Environmental No underlying causes
Gastroenterologic No underlying causes
Genetic No underlying causes
Hematologic No underlying causes
Iatrogenic No underlying causes
Infectious Disease No underlying causes
Musculoskeletal/Orthopedic No underlying causes
Neurologic No underlying causes
Nutritional/Metabolic No underlying causes
Obstetric/Gynecologic No underlying causes
Oncologic No underlying causes
Ophthalmologic No underlying causes
Overdose/Toxicity No underlying causes
Psychiatric No underlying causes
Pulmonary No underlying causes
Renal/Electrolyte No underlying causes
Rheumatology/Immunology/Allergy No underlying causes
Sexual No underlying causes
Trauma No underlying causes
Urologic No underlying causes
Miscellaneous No underlying causes

Causes in Alphabetical Order

Differentiating Parkinsonism from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms | Physical Examination |Laboratory Findings | CT | MRI | Other Imaging Findings |Other Diagnostic Studies

Treatment

Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies

Case Studies

Case #1

Template:WH Template:WS